EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY)

Kennedy S Ramos iD, Soufiane Nassiri, Leonoor F J Wijdeveld, Reinier L van der Palen, Myrthe F Kuipers, Mellanie True Hills, Pieter Slijkerman, Daniel H van Raalte, M Louis Handoko, Natasja M S de Groot, Nimrat Grewal, Robert J M Klautz und 2 weitere

Cardiovascular Drugs and Therapy · 2025

DOI: 10.1007/s10557-025-07693-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Kennedy S Ramos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boel…. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Atrial Fibrillation, Cardiac Surgical Procedures, Diterpenes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NWO, Netherlands Heart Foundation, Innovation Exchange Amsterdam.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Interestingly, 30–50% of patients undergoing elective cardiothoracic surgery develop postoperative AF (PoAF). Unfortunately, preventive PoAF therapy is still suboptimal. In our previous studies, we showed that oral Geranylgeranylacetone (GGA) administration increased cardioprotective heat shock protein (HSP) protecting against AF onset and progression in clinically relevant animal model studies.

Methods

The GENIALITY study is a phase II single-center, double-blind, placebo-controlled randomized trial comparing the efficacy of GGA in preventing PoAF.

Participants

( N = 146) are adult patients, without any registered history of AF, undergoing elective open-heart surgery for valvular disease, coronary artery bypass grafting, or concomitant, and are allocated with ratio 1:1 in treatment or placebo groups. Daily administration of 300 mg of GGA or placebo starts 5 days before until 3 days after surgery. Cardiac rhythm will be monitored using a Holter monitoring post-surgery until hospital discharge. Additionally, blood samples, right atrial appendage tissue, and epicardial adipose tissue will be collected to assess proteostasis levels.

Results

The primary endpoint is the assessment of PoAF incidence in the GGA group compared to the placebo group. Secondary endpoints include the evaluation of HSP levels through biochemical analysis in both blood and atrial tissue.

Conclusion

The GENIALITY study aims to reduce PoAF incidence in the GGA group compared to the placebo group. Herewith, we expect to obtain proof of concept for a beneficial effect of GGA in preventing PoAF in patients undergoing cardiothoracic surgery. Trial Registration Clinical Trial Information System (CTIS) registry: 2024–514743-28–00. Authorized on September 30th 2024.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Arrhythmia AgentsAtrial FibrillationCardiac Surgical ProceduresDiterpenesHeart RatePostoperative ComplicationsFemaleHumansMaleMiddle AgedDouble-Blind MethodIncidenceRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Cardiothoracic surgeryHeat shock proteinsPostoperative atrial fibrillationPrevention

Substanzen

Anti-Arrhythmia AgentsDiterpenesgeranylgeranylacetone

Autor:innen und Institutionen

  • Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands. k.silvaram…
  • Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands.
  • AFIP Foundation, Amsterdam, The Netherlands.
  • Stopafib.Org, American Foundation for Women'S Health, Decatur, TX, USA.
  • Innovation Exchange Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.

ORCID-Profile: Kennedy S Ramos

Förderung

  • NWO
  • Netherlands Heart Foundation
  • Innovation Exchange Amsterdam
  • Atrial-Fibrillation-Innovation-Platform
  • StopAfib.org

Zitieren

APA

S Ramos, K., Nassiri, S., Wijdeveld, L. F. J., van der Palen, R. L., Kuipers, M. F., Hills, M. T., Slijkerman, P., van Raalte, D. H., Handoko, M. L., de Groot, N. M. S., Grewal, N., Klautz, R. J. M., Eringa, E. C., & Brundel, B. J. J. M. (2025). Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY). Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-025-07693-2

Vancouver

S Ramos K, Nassiri S, Wijdeveld LFJ, van der Palen RL, Kuipers MF, Hills MT, et al. Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY). Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-025-07693-2

BibTeX
@article{SRamos2025,
  author = {S Ramos, Kennedy and Nassiri, Soufiane and Wijdeveld, Leonoor F J and van der Palen, Reinier L and Kuipers, Myrthe F and Hills, Mellanie True and Slijkerman, Pieter and van Raalte, Daniel H and Handoko, M Louis and de Groot, Natasja M S and Grewal, Nimrat and Klautz, Robert J M and Eringa, Etto C and Brundel, Bianca J J M},
  title = {Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY)},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2025},
  doi = {10.1007/s10557-025-07693-2}
}
Kostenlos starten →